Our Annual Review 2019

Download our 2019 Annual Review here.

Latest

Over Reacting to an Absence of PINK

Two genes when mutated, PINK1 and PARKIN, are associated with young onset Parkinson's. Exactly why they increase the risk of developing Parkinson's has long been a mystery, but now Canadian scientists have published research that might be able to explain this increased susceptibility...
The Grand Garden Fete

Join supporters Sue & Lizzy for a fantastic afternoon at the Grand Garden Fete on Sunday 11th August in support of The Cure Parkinson's Trust.
The Glencoe Marathon Gathering

This September take on the epic Glencoe Marathon or the Mamores Half Marathon in the stunning Scottish Highlands in support of CPT.
Jon Selby and friends take on the Cotswold Way Challenge

CPT supporter Jon Selby along with two friends recently took on the brilliant Cotswold Way Challenge. Walking from the historic Royal Crescent in Bath to Cheltenham in Gloucestershire the team covered the 100km distance with 2,000m of climb in just two days! Here is Jon’s fantastic story...

Over Reacting to an Absence of PINK

Two genes when mutated, PINK1 and PARKIN, are associated with young onset Parkinson's. Exactly why they increase the risk of developing Parkinson's has long been a mystery, but now Canadian scientists have published research that might be able to explain this increased susceptibility...
From Dreams to Parkinson's

Professor Michele Hu has published an interesting article providing an overview of the 'prodromal phase' or the period before diagnosis in Parkinson's...
The Appendix and Parkinson's

Although its exact role isn’t yet clear because findings have been conflicting, in this easy-to-read overview the link between the appendix and risk of developing Parkinson's is discussed...
The Rationale for the TRANSEURO Study

The TRANSEURO study is being funded by The Cure Parkinson's Trust and is investigating cell transplantation as a restorative therapy for people with Parkinson's. In this article, Prof Roger Barker explains the rational behind the trial design...
Not Easy for EGCG

Disappointing results for Epigallocatechin-gallate (EGCG) as study fails to show evidence of modifying disease progression in patients with Multiple System Atrophy.
Research that has Gone to the Dogs

It is hoped that Parkinson's detecting dogs will be able to help with early detection of Parkinson's, aid in the diagnosis and improve our understanding the condition.
New Drug to Target Alpha-Synuclein

Scientists are to develop a drug which blocks the enzyme which prevents the natural breakdown of the toxic protein alpha-synuclein...
Hilton Food Group's Third Annual Charity Golf Day

The Cure Parkinson’s Trust were delighted to be one of beneficiary charities of the Hilton Food Group’s third annual charity golf day, held at Hanbury Manor on the 6th June.
More Evidence that Parkinson's Originates in the Gut

A new study published in the journal Neuron has found more evidence that Parkinson's starts in cells in the gut and journeys to the brain via the body's neurons.
The Behaviours of Alpha-Synuclein

Researchers are beginning to better understand the behaviours of the alpha-synuclein protein implicated in Parkinson's. In this article, Linked Clinical Trials committee member David Sulzer discusses the findings...

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.
Science news

Read the latest Parkinson's science and research news here.
Trials - Repurposed drugs

Our international Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Apply for Funding
The NAC Trial - the facts
Our story
Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
The Grouse & Grape Luncheon

The Grouse and Grape Luncheon will return to Spencer House on the 8th October 2019 where over 300 guests will be welcomed to take part in this flourishing networking event, all in the aid of The Cure Parkinson's Trust.

Science news

Read the latest Parkinson's science and research news here. Read more

The Cure Collective

The Cure Collective is an opportunity to join like-minded individuals who are committed to help drive forward the quest to find a cure for Parkinson’s... Read more

Our Annual Review 2019

Our Annual Review 2019 - your online publication here... Read more

Parkinson's Movement

The Science of Parkinson's - Dr Simon Stott

Leave a gift in your Will

A donation to The Cure Parkinson's Trust will make a huge difference to our research to slow, stop or even reverse Parkinson's. Read more